Illumina (NASDAQ:ILMN) Sets New 1-Year High – Time to Buy?

Illumina, Inc. (NASDAQ:ILMN)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $226.84 and last traded at $224.99, with a volume of 1917648 shares changing hands. The stock had previously closed at $223.22.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Canaccord Genuity Group lifted their target price on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Finally, Leerink Partners boosted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $188.40.

Illumina Stock Performance

The company has a market cap of $34.38 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45. The firm’s 50 day simple moving average is $192.98 and its 200-day simple moving average is $155.18. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,034,688 shares of company stock worth $417,970,281 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Fiduciary Financial Advisors acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the 2nd quarter worth approximately $32,000. Rakuten Securities Inc. acquired a new position in Illumina during the second quarter worth $33,000. Elyxium Wealth LLC purchased a new position in shares of Illumina during the fourth quarter worth $25,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina in the fourth quarter valued at $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.